Literature DB >> 17804466

Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.

A Försti1, H Lei, B Tavelin, K Enquist, R Palmqvist, A Altieri, G Hallmans, K Hemminki, P Lenner.   

Abstract

BACKGROUND: Extracellular matrix degradation, mediated by the urokinase plasminogen activation (uPA) system, is a critical step in tumor invasion and metastasis. High tumor levels of uPA and its inhibitor PAI-1 have been correlated with poor cancer prognosis. We examined four single nucleotide polymorphisms (SNPs) with a potential effect on expression of genes in the uPA system for their role in colorectal cancer susceptibility and prognosis. PATIENTS AND METHODS: We genotyped the SNPs in 308 Swedish incident colorectal cancer patients with up to 16 years of follow-up and in 585 age- and sex-matched controls. We evaluated the associations between genotypes and colorectal cancer and Dukes' stage. Survival probabilities were compared between different subgroups.
RESULTS: Patients with PAI-1 -675 5G/5G genotype had better survival than patients with 4G/4G or 4G/5G genotypes when they had Dukes' stage A or B tumors (P = 0.023 and P = 0.015, respectively). No statistically significant association was observed between the SNPs and the risk of colorectal cancer or Dukes' stage.
CONCLUSIONS: Our results suggest a role for the PAI-1 genotype in colorectal cancer prognosis, but further studies are needed to evaluate the impact of our finding in the clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804466     DOI: 10.1093/annonc/mdm361

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

2.  Aneuploidy-associated gene expression signatures characterize malignant transformation in ulcerative colitis.

Authors:  Marco Gerling; Kari Nousiainen; Sampsa Hautaniemi; Stefan Krüger; Britta Fritzsche; Nils Homann; Hans-Peter Bruch; Gert Auer; Uwe J Roblick; Thomas Ried; Jens K Habermann
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

3.  PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.

Authors:  Shangqian Wang; Qiang Cao; Xiaoxiang Wang; Bingjie Li; Min Tang; Wanqing Yuan; Jianzheng Fang; Jian Qian; Chao Qin; Wei Zhang
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.

Authors:  Zhen Xu; Li-Li Meng; Jizong Lin; Yunbiao Ling; Shu-Xian Chen; Nan Lin
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

5.  Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.

Authors:  Eun Ran Kim; Mun Hee Yang; Yeun Jung Lim; Jin Hee Lee; Dong Kyung Chang; Young-Ho Kim; Hee Jung Son; Jae J Kim; Jong Chul Rhee; Jin Yong Kim
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

6.  Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility.

Authors:  Jisu Oh; Hui Jeong An; Jung Oh Kim; Hak Hoon Jun; Woo Ram Kim; Eo Jin Kim; Doyeun Oh; Jong Woo Kim; Nam Keun Kim
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

7.  PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.

Authors:  Xin Xu; Yanqi Xie; Yiwei Lin; Xianglai Xu; Yi Zhu; Yeqing Mao; Zhenghui Hu; Jian Wu; Hong Chen; Xiangyi Zheng; Jie Qin; Liping Xie
Journal:  Exp Ther Med       Date:  2012-10-02       Impact factor: 2.447

8.  PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.

Authors:  Jiaxi Wang; Yuanyuan Peng; Hejia Guo; Cuiping Li
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.